Cargando…
Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
Advanced renal cell carcinoma (RCC) remains a challenging, major health problem. Recent advances in understanding the fundamental biology underlying one form of RCC, ie, clear cell (or conventional) RCC, have opened the door to a series of targeted agents, such as the tyrosine kinase inhibitors (TKI...
Autor principal: | Clark, Peter E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921256/ https://www.ncbi.nlm.nih.gov/pubmed/20714356 |
Ejemplares similares
-
Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
por: Lang, Joshua M., et al.
Publicado: (2010) -
Pharmacotherapy Options in Advanced Renal Cell Carcinoma: What Role for Pazopanib?
por: Harrison, Michael R.
Publicado: (2011) -
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010) -
Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011) -
Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)